← All trials
NCT05874336
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 17, 2020
- Primary completion
- Aug 11, 2020
- Completion date
- Aug 11, 2020
- First posted
- May 24, 2023
- Last posted
- May 24, 2023
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Galmed Pharmaceuticals LtdLead sponsor
- QuotientCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.